ChinaBio Today submits:
Three of big pharma’s biggest companies, Merck (NYSE: MRK), Lilly (NYSE: LLY) and Pfizer (NYSE: PFE), have banded together to create an Asian not-for-profit company that will construct a pharmacogenomic cancer database in Singapore (see story). The database will compile its information using 2,000 tissue samples from patients with lung and [...]
At times it is instructive to go back in time and read some of the seminal pieces which describe the mood of that day. Worst case, you get a reminding glimpse of the prevailing thoughts (and giggle at their naïveté), but if you are lucky, you uncover a long forgotten treasure that provides you with [...]
ChinaBio Today submits:
WuXi PharmaTech (NYSE: WX) plans to continue its growth by expanding into biotech, safety evaluation and manufacturing. In fact, to make the growth a reality, the company invests about $60 million each year in capital expenditures.
The overview of WuXi’s outlook and operations was published recently in the China Daily, including [...]
Robert Salomon submits:
Simon Johnson at Baseline Scenario, whose work I’ve immensely enjoyed reading over the years, posted a wonderful excerpt from his testimony before a Congressional panel about how best to put pressure on China to revalue the yuan (see Should We Fear China?).
China is the largest holder of official foreign currency reserves in [...]
ChinaBio Today submits:
China Cord Blood Corporation (NYSE: CO) has acquired a 19.92% equity interest in Shandong Cord Blood Bank (SCBB) for $20.5 million, which will be paid in cash. China Cord Blood already projects an investment yield in this year of 5% or about $1 million from the purchase. More importantly, China Cord [...]
<<<Return to Part III
Lithium and China
Complete Story »
Russ Winter submits:
"A country that appears peaceful and stable may encounter unexpected crises. There are structural problems in China’s economy, which cause unsteady, unbalanced, uncoordinated and unsustainable development." – Chinese Premier Wen Jiabao, 2007
Today’s post does have extra links that I hope you’ll read, as this is not a post that one can just [...]
ChinaBio Today submits:
China Aoxing (CAXG.OB) will collaborate with QRxPharma Limited (QRXPY.PK), a clinical stage Australian pharma, to develop MoxDuo®IV for the China market. MoxDuoIV is an IV formulation of QRxPharma’s patented morphine and oxycodone Dual-Opioid™ technology for the acute treatment of moderate to severe pain.
China Aoxing will fund development of MoxDuo®IV for [...]
ChinaBio Today submits:
Three of big pharma’s biggest companies, Merck (NYSE: MRK), Lilly (NYSE: LLY) and Pfizer (NYSE: PFE), have banded together to create an Asian not-for-profit company that will construct a pharmacogenomic cancer database in Singapore. The database will compile its information using 2,000 tissue samples from patients with lung and gastric cancer. [...]
China OTC Player submits:
In a quiet filing made last week, I discovered that an investment firm called First Wilshire Securities had scooped up more than 1.9 million shares of Shiner International (BEST), the Hainan-based manufacturer of packaging film for food and other products. Who is First Wilshire Securities? I decided to find out more about [...]